A PHASE III RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF DURVALUMAB IN COMBINATION WITH CHEMOTHERAPY AND BEVACIZUMAB, FOLLOWED BY MAINTENANCE DURVALUMAB, BEVACIZUMAB AND OLAPARIB IN NEWLY DIAGNOSED ADVANCED OVARIAN CANCER PATIENTS (DUO-O).

AstraZeneca AB,0 个研究点目标入组 0 人开始时间: 2020年2月6日最近更新: 2024年8月20日

适应症

试验速览

阶段: 未知
状态: 招募中
发起方: AstraZeneca AB,

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•Informed consent
•1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent forms (ICFs) and in this protocol. All patients must sign both the Pre-screen ICF and main ICF: (i) The separate (Pre-screen) ICF will be provided for the mandatory tBRCA testing.
•(ii) The main ICF for participation in the study. The main consent form includes a separate consent for the optional Genomics Initiative research component of the study (if a patient declines to participate in this research, there will be no penalty or loss of benefit to the patient and the patient will not be excluded from other aspects of the study).
•tBRCA mutation status
•Patients MUST meet the following criteria to be enrolled in the study
•2. Patients must provide sufficient formallin fixed, paraffin embedded (FFPE) tumour sample suitable for the Myriad myChoice HRD Plus test
•Determination of tBRCAm status: Subject to local regulations, all patients must provide an FFPE tumour specimen sample for tissue-based BRCA1/2 gene testing using the clinical trial assay (CTA) known as the myChoice HRD Plus assay. The results of this test MUST be available prior to Day 1 of Cycle 2.
•If the test results indicate that the patient has deleterious or suspected deleterious mutation in BRCA1 or BRCA2, the patient may (subject to fulfilling all other selection criteria) be eligible for allocation to the tBRCAm single arm cohort of the study.
•• If the test results indicate that the patient has no detected deleterious or suspected deleterious mutation in BRCA1 and BRCA2 the patient may (subject to fulfilling all other selection criteria) be eligible for randomisation in one of 3 non-tBRCAm arms.
•• If a valid tBRCAm test result is not obtained prior to Day 1 of Cycle 2, the patient will be withdrawn from the study and considered as a screen failure.
•The cohort allocation and randomisation procedures are provided in Section 6.3.1.
•Patients MUST meet the following criteria prior to receiving Cycle 1 of chemotherapy. Patients MUST meet the following criteria prior to allocation/randomisation except for criteria 7, 8, and 9
•3. Patients must be aged ≥18 years of age. For patients enrolled in Japan that are aged <20 year, a written informed consent should be obtained from the patient and her legally acceptable representative*.
•Type of patient and disease characteristics
•4. Female patients with newly diagnosed, histologically confirmed, advanced (Federation Internationale de Gynecologie et d´Obstetrique [FIGO] Stage III or IV) high grade epithelial ovarian cancer including high grade serous, high grade endometriod, clear cell ovarian cancer or carcinosarcoma (malignant mixed Mullerian tumour [MMMT] of the ovary, provided high grade epithelial component is present); ovarian cancer = ovarian, primary peritoneal cancer and / or fallopian-tube cancer.
•5. All patients must have had either*: − Upfront primary surgery
•− OR, plan to undergo chemotherapy with interval debulking surgery
•6. Patients must have a life expectancy of at least 12 months*.
•7. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of Day 1 of Cycle 1 as defined below: − Haemoglobin (Hb) ≥10.0 g/dL
•− Absolute neutrophil count (ANC) ≥1.5 x 109/L
•− Platelet count &

排除标准

•Medical conditions
•1Non-epithelial ovarian cancer, borderline tumours, low grade epithelial tumours or mucinous histology.
•2Active or prior documented autoimmune or inflammatory disorders (including but not limited to inflammatory bowel disease [eg, colitis or Crohn’s disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, Wegener syndrome [granulomatosis with polyangiitis, Graves’ disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]).
•3History of another primary malignancy
•4Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML*.
•5Patients with known brain metastases.
•6History of leptomeningeal carcinomatosis*
•7History of active primary immunodeficiency*
•8Active infection including tuberculosis (TB) (clinical evaluation that includes clinical history of TB, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result), hepatitis C (HCV), or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc], followed by a negative hepatitis B virus DNA test and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA
•For additional Information please refer to the protocol

研究者

发起方

AstraZeneca AB,

相似试验

已完成

不适用

A PHASE III RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL TO EVALUATE EFFICACY AND SAFETY OF TIOTROPIUM INHALATION SOLUTION DELIVERED VIA RESPIMAT® INHALER (2,5 Y 5 µg ONCE DAILY) COMPARED WITH PLACEBO AND SALMETEROL HFA MDI (50 µG DOS VECES POR DIA) OVER 24 WEEKS IN PATIENTS WITH MODERATE PERSISTENT ASTHMA-J45J45

PER-088-10Boehringer Ingelheim,44

招募中

不适用

A PHASE III DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF CAPIVASERTIB + ABIRATERONE VERSUS PLACEBO + ABIRATERONE AS TREATMENT FOR PATIENTS WITH DE NOVO METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) CHARACTERISED BY PTEN DEFICIENCY (CAPITELLO-281)-C61 Malignant neoplasm of prostateMalignant neoplasm of prostateC61

PER-049-20AstraZeneca AB,

进行中（未招募）

1 期

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients with Early Relapsing Recurrent Triple-Negative Breast CancerTriple-Negative Breast Cancer (TNBC)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-005119-42-PTF. Hoffmann-La Roche Ltd597

进行中（未招募）

1 期

EUCTR2016-005119-42-HUF. Hoffmann-La Roche Ltd350

进行中（未招募）

1 期

EUCTR2016-005119-42-PLF. Hoffmann-La Roche Ltd572